Navigation Links
Diabetics to get Relief from Cheaper Drugs

The Federal Government’s decision to list two new drugs on the Pharmaceutical Benefits Scheme will allow diabetics to have better access to treatment from October.//

According to Health Minister Tony Abbott long-lasting injectable insulins Levemir and Lantus will be subsidized from October 1, at a cost of $145 million over the next three years.

These drugs have several medical advantages over current subsidized treatments.

Daily injections are needed by all type-one diabetics and some type-two diabetics to control their blood sugar levels.

Presently about 210,000 Australians with type one and type two diabetes will qualify for the drugs, and about 110,000 people are expected to use them in the first year of listing.

By 2009 about 160,000 patients are expected to benefit from this with each paying $9.40 for concession card holders and non-concessional patients paying about $59 for a year's supply.

According to Donald Chisholm, professor of endocrinology at Sydney's St Vincent's Hospital, these drugs could help to bring down the number of injections for some patients because of the longer lasting effect compared to other common insulin.

Prof Chisholm said that these drugs are absorbed slowly during the 24 hours after an injection, thereby preventing a potentially dangerous peak in insulin levels as well as lowering the risk of hypoglycaemia
'"/>




Page: 1

Related medicine news :

1. Cinnamon May Help Diabetics
2. Heart disease threat starts early in life for Diabetics
3. Diabetics and their babies
4. Beta-Carotene May Aid Diabetics
5. Diabetics prone to periodontitis
6. Blood Vessel Surgery Safe for Diabetics
7. Marriage does good for Diabetics
8. Niacin Safe for Diabetics
9. Diabetics & Foot infections
10. Diabetics Need to Guard Against Nail Fungus
11. Pancreas Transplant for Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Diabetics get Relief from Cheaper Drugs

(Date:7/25/2008)...alif., July 25 /PRNewswire/ -- AutoGenomics, Inc. ...tatement on Form S-1 with the,Securities and Excha...blic,offering of shares of its common stock. The n... of which are expected to be offered by,AutoGenomi...ve not yet been,determined., J.P. Morgan Securiti...
(Date:7/25/2008)... The Retina Group of New York will prese...cular degeneration especially designed for seniors...ic Library at 116 Merritts Road, Farmingdale, NY 1...ndance is free and refreshments will be provided. ...-6100. , Hicksville and H...
(Date:7/25/2008)... Columbus-based law firm represents Pick...ef purchased at Columbus-area Kroger store , ...uly 25, 2008 -- http://www.donaheyohioinjurylawye... personal injury law firms in central Ohio, has fi... Court (Case No. 08CV9804) against The Kroger Co.,...
(Date:7/24/2008)...inn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (...port its 2008 second quarter and,year-to-date fina... quarter,and year-to-date financial results on Mon...ours., The company will host a conference call an...tern Time) on Tuesday, July 29, 2008. ev3,manageme...
Breaking Medicine News(10 mins):Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
...ors of All India Institute of Medical Sciences (AI...ll //in Lok Sabha on Thursday intensified with fiv...ike - Dr Anil Sharma, spokesman of the AIIMS Resid...the doctors would continue attending duty and serv...
...Ease Dietary Supplement, a product containing the ...ndent on it when used just for few months. // Est...which should be consumed only under a practitioner...r of side effects like loss of memory, confusion, ...
... wish-list of many scientists and sufferers the wo...–child of an //Australian scientist, whose perseve...th of cancer cells, seems to have paid off. Prof...king on his ‘baby’ for the past 20 years, may just...
...mptoms of high fever and bodyache has killed 12 ch...g to official sources, 12 children died in two or ...strict due to the disease commonly referred as 'kh...a dozen children were suffering from the same dise...
Other Medicine News:
(Date:7/24/2008)... Ortho-McNeil Neurologics, a,division of Ortho-McN...,that the U.S. Food and Drug Administration (FDA) ...topiramate), based on studies submitted in,respons...he use of TOPAMAX,in pediatric patients aged 1 to ...on to granting pediatric exclusivity, the FDA is c...
(Date:7/24/2008)...cology Patient Accrual, DENVER, July 24 /PRNewswi...anization (RMO), has contracted with five leading ...ite management services for their,clinical trials ...The new,trials include the following disease indic...tic Breast Cancer, Metastatic Sarcoma, Chronic Mye...
(Date:7/23/2008)... print edition of Clinical Ch.../- A Roche Diagnostics-sponsored,pilo...e natriuretic peptide,(NT-proBNP) confirms the pot...in predicting the risk of cardiovascular adverse e...al anti-inflammatory drugs of,the COX inhibitor cl...
(Date:7/23/2008)...Code BioPharmaceutics, Inc.,an emerging biopharma...,results demonstrating the utility of their lead d...chronic blood disorder paroxysmal nocturnal,hemogl...nted at the XXII,International Complement Workshop...only treatment currently available for PNH patient...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 1Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 2Origin of cells for connective tissues of skull and face challenged 3415 1Origin of cells for connective tissues of skull and face challenged 3415 2Origin of cells for connective tissues of skull and face challenged 3415 3Journal of Ultrasound In Medicine features bioeffects consensus report 20179 1Graduates Forced to Join Millions of Uninsured Americans 20174 1Graduates Forced to Join Millions of Uninsured Americans 20174 2Graduates Forced to Join Millions of Uninsured Americans 20174 3
...007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...r,DF) 300 mg as a potential treatment for chronic ... efficacy endpoint. The study shows,that Viread is...l,drug Hepsera(R) (adefovir dipivoxil) among patie...
...-FirstCall/ --,NeurogesX, Inc. announced today the...se 3 trial in postherpetic neuralgia (PHN).,Misha-... University,of Wisconsin in Madison and lead acade...present the results of the study in a,June 8 poste...Neuropathic Pain in Berlin, Germany. Dr. Backonja,...
Other Medicine Technology:Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 2NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 3NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 4
...eeds I-125 are brachytherapy sources which are imp...mors, especially in the prostate. The seeds remain...ic effect, i.e. after radioactive decay is complet...ey are supplied in a sterile form. Isoseeds I-125 ...
...mirrors for complete anterior chamber angle viewin...or easy handling and stability. Choice large or sm...llows static or dynamic gonioscopy without methylc... coating protects mirrors and is compatible with m...
Three mirrors of 64, 67 and 73 and a small diameter contact surface for use without methylcellulose. The fundus can be viewed through the central axis of the lens. Multi-layer polymer coating protect
West lacrimal cannula blunt tip with side port.
Medicine Products: